Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Accumulated Expenses (2020 - 2025)

Caribou Biosciences has reported Accumulated Expenses over the past 6 years, most recently at $16.5 million for Q4 2025.

  • Quarterly Accumulated Expenses fell 30.0% to $16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Dec 2025, down 30.0% year-over-year, with the annual reading at $16.5 million for FY2025, 30.0% down from the prior year.
  • Accumulated Expenses was $16.5 million for Q4 2025 at Caribou Biosciences, down from $19.3 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $25.4 million in Q3 2024 and troughed at $11.2 million in Q1 2022.
  • The 5-year median for Accumulated Expenses is $16.5 million (2025), against an average of $17.5 million.
  • Year-over-year, Accumulated Expenses soared 51.39% in 2024 and then decreased 30.0% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $13.1 million in 2021, then increased by 22.4% to $16.1 million in 2022, then skyrocketed by 31.44% to $21.1 million in 2023, then increased by 11.76% to $23.6 million in 2024, then fell by 30.0% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Accumulated Expenses are $16.5 million (Q4 2025), $19.3 million (Q3 2025), and $20.5 million (Q2 2025).